Status:
COMPLETED
Benefit of DAA Therapy in HCV Monoinfected and HIV-HCV Coinfected Patients With Mixed Cryoglobulinemia
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Hepatitis C, Chronic
Mixed Cryoglobulinemia
Eligibility:
All Genders
18+ years
Brief Summary
Mixed cryoglobulinemia (MC) is common in patients with chronic hepatitis C virus (HCV) infection. Direct-acting antiviral (DAA) regimens are today very effective with sustained virological response ra...
Detailed Description
We focused on HCV patients with or without HIV with MC who had at least one cryoglobulin level assessment before and after DAA therapy and investigated the impact of DAA therapy on cryoglobulin cleara...
Eligibility Criteria
Inclusion
- hepatitis C virus (HCV) infected patients
- symptomatic or asymptomatic mixed cryoglobulinemia
- coinfected or not with HIV
- treated by direct-acting antiviral (DAA) treatment
- at least one cryoglobulin measurement before and after DAA
Exclusion
- \-
Key Trial Info
Start Date :
March 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2017
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT03342261
Start Date
March 1 2017
End Date
November 1 2017
Last Update
November 14 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospices Civils de Lyon - Croix-Rousse Hospital
Lyon, France, 69004